Pharma BD Deal Intelligence
Summit Therapeutics partners with Akeso in a deal worth up to $5 billion to in-license ivonescimab for development and commercialization in the US, Canada,…
Summit committed an upfront payment of $500 million for ivonescimab rights with potential deal value up to $4.5 billion.
At ASCO 2026, HARMONi-6 (1L advanced squamous NSCLC) showed ivonescimab+chemo improved OS vs tislelizumab+chemo (HR 0.66, ~28 vs ~24 mo median OS);…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Summit Therapeutics licensed exclusive rights to ivonescimab, a PD-1/VEGF bispecific antibody, from Akeso for markets outside Greater China (US, Canada, Europe, Japan) in a December 2022 collaboration worth $500M upfront and up to $5B with milestones (deal closed January 2023). Development has since advanced materially: the U.S. FDA accepted Summit's BLA on January 29, 2026 for ivonescimab plus chemotherapy in EGFR-mutated NSCLC post-3rd-generation TKI (Phase III HARMONi, PFS HR 0.52), with a PDUFA goal action date of November 14, 2026. At ASCO 2026, the Akeso-run Phase III HARMONi-6 showed a statistically significant overall-survival benefit versus tislelizumab plus chemotherapy in first-line squamous NSCLC (OS HR 0.66). The global HARMONi-3 trial (first-line non-squamous NSCLC vs pembrolizumab) is the pivotal US readout, with final PFS data expected in the second half of 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Summit Therapeutics plc / Akeso Inc. (this deal) | 2023 | $4.5B | 79 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2023 deals · Oncology deals